Discover the Latest in Biomedical Research Innovation

If your treatment raises GAPDH by half, every target you normalize to it looks a third lower, even if nothing changed. Few labs check: studies use 1.2 reference genes on average, and only 15% test a panel first. This guide covers choosing candidates from different pathways, validating them with geNorm and NormFinder, and what MIQE 2.0 now asks you to report.

Your drug works in wild-type mice and not in the knockout, so the effect depends on the gene. That conclusion does not follow, and in one major review of top journals, half the papers that needed the right test got it wrong. This two-way ANOVA interaction SOP runs the correct analysis in GraphPad Prism, from data entry to a reportable result, with a worked example in which the naive reading and the right answer disagree.

Sophie 4.5 is live. It keeps everything that made 4.0 work and sharpens what matters: the core chat is ~40% more intelligent at the same speed, and the Regulatory Architect is 3x faster, ~25% smarter, and now wired directly into the CFR database for more accurate device classification. The Visualizer and Analytics engines get intelligence and speed bumps, and a wave of UI/UX updates came straight from how people used 4.0. Here's everything new in CLYTE's Sophie 4.5.

A former FDA reviewer ran a test for us. He took a real problem — a device with an endotoxin level his team couldn't lower — and tried to bait four AIs into approving a workaround he knew was wrong. One by one, ChatGPT, Gemini, and Claude came around and told him to proceed. Sophie refused: it cited the guidelines, held the line when he pushed, and sent him to the FDA. In regulated work, an AI eager to agree is a liability. Here's what happened — plus a test you can run yours

We took notes at NY Tech Week 2026. In an a16z masterclass, Deel's Anish Acharya and Shuo Wang made the case that the most defensible AI is built where decisions carry liability — the ground a model can't own. IBM's Gary Cohn added the data-sovereignty argument for small, specialized, walled-off models. For an AI built for FDA-regulated biomedical research, that's the whole thesis. Here's what we took from the week — and the a16z session is now a podcast on our channel.